345 related articles for article (PubMed ID: 27577071)
21. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
22. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Anderson AC; Joller N; Kuchroo VK
Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
[TBL] [Abstract][Full Text] [Related]
23. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
[TBL] [Abstract][Full Text] [Related]
24. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
Ichihara F; Kono K; Takahashi A; Kawaida H; Sugai H; Fujii H
Clin Cancer Res; 2003 Oct; 9(12):4404-8. PubMed ID: 14555512
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
[TBL] [Abstract][Full Text] [Related]
28. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
29. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
[TBL] [Abstract][Full Text] [Related]
30. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
Front Oncol; 2019; 9():1066. PubMed ID: 31709176
[No Abstract] [Full Text] [Related]
31. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients.
Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L
Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract][Full Text] [Related]
34. PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis.
Qiu MK; Wang SC; Dai YX; Wang SQ; Ou JM; Quan ZW
PLoS One; 2015; 10(6):e0128523. PubMed ID: 26035207
[TBL] [Abstract][Full Text] [Related]
35. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
Thommen DS; Schreiner J; Müller P; Herzig P; Roller A; Belousov A; Umana P; Pisa P; Klein C; Bacac M; Fischer OS; Moersig W; Savic Prince S; Levitsky V; Karanikas V; Lardinois D; Zippelius A
Cancer Immunol Res; 2015 Dec; 3(12):1344-55. PubMed ID: 26253731
[TBL] [Abstract][Full Text] [Related]
36. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Datar I; Sanmamed MF; Wang J; Henick BS; Choi J; Badri T; Dong W; Mani N; Toki M; Mejías LD; Lozano MD; Perez-Gracia JL; Velcheti V; Hellmann MD; Gainor JF; McEachern K; Jenkins D; Syrigos K; Politi K; Gettinger S; Rimm DL; Herbst RS; Melero I; Chen L; Schalper KA
Clin Cancer Res; 2019 Aug; 25(15):4663-4673. PubMed ID: 31053602
[TBL] [Abstract][Full Text] [Related]
37. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
Nakano M; Ito M; Tanaka R; Yamaguchi K; Ariyama H; Mitsugi K; Yoshihiro T; Ohmura H; Tsuruta N; Hanamura F; Sagara K; Okumura Y; Nio K; Tsuchihashi K; Arita S; Kusaba H; Akashi K; Baba E
Cancer Sci; 2018 Sep; 109(9):2986-2992. PubMed ID: 30187676
[TBL] [Abstract][Full Text] [Related]
38. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
39. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
40. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]